Press Release Archive
Press Releases
August 2019
08.21.2019 Medicines U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer 08.21.2019 Finance Investments Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina 08.20.2019 Research The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance 08.14.2019 Medicines Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products 08.02.2019 Research Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis 08.01.2019 Partnerships Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company
July 2019
07.31.2019 Partnerships BioInvent announces selection of first target discovered by BioInvent’s proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc. 07.30.2019 Finance Investments Pfizer Completes Acquisition of Array Biopharma 07.29.2019 Finance Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT 07.29.2019 Finance PFIZER REPORTS SECOND-QUARTER 2019 RESULTS 07.29.2019 Finance Research Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine 07.26.2019 Medicines Pfizer Statement on Update to XELJANZ® (tofacitinib) Prescribing Information in the United States
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.